-
Company Insights
New![]()
Innovation and Patenting activity of Ardelyx Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ardelyx Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-101 in Uveal Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-101 in Uveal Melanoma Drug Details:ST-101 is under development for the treatment of hematologic malignancies including...
-
Company Profile
![]()
Ardelyx Inc – Company Profile
Ardelyx Inc (Ardelyx), is a pharmaceutical company. It is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease, constipation-predominant irritable bowel syndrome, and hyperkalemia, in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership...
Add to Basket -
Product Insights
![]()
Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Report Overview Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics. The Hyperphosphatemia in chronic kidney disease pipeline...
-
Product Insights
![]()
Net Present Value Model: Ibsrela
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ibsrela Drug Details Tenapanor hydrochloride (Ibsrela)...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – RDX-013
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RDX-013 Drug Details RDX-013 is under development for the treatment of hyperkalemia in patients...
-
Product Insights
![]()
Irritable Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of irritable bowel syndrome include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones. The Irritable Bowel Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
![]()
Hyperphosphatemia – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Hyperphosphatemia - Global Clinical Trials Review, H2, 2021" provides an overview of Hyperphosphatemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Sector Analysis
![]()
Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Global Drug Forecast and Market Analysis to 2030
CKD is a chronic condition in which patients suffer from an irreversible and progressive loss in renal function over many months or years, ultimately resulting in end-stage renal disease and the requirement for renal replacement therapy. CKD manifests when both kidneys are damaged sufficiently to hinder the removal of metabolic products from the body and the ability to provide mineral balance. The Centers for Disease Control and Prevention states that approximately 96% of people with kidney damage or mild to...
-
Product Insights
![]()
Hyperphosphatemia Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Hyperphosphatemia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Hyperphosphatemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.